NYSE - Delayed Quote USD

Enovis Corporation (ENOV)

36.06
+0.33
+(0.92%)
At close: May 16 at 4:00:02 PM EDT
36.08
+0.02
+(0.06%)
After hours: May 16 at 5:16:11 PM EDT
Loading Chart for ENOV
  • Previous Close 35.73
  • Open 35.63
  • Bid 31.77 x 900
  • Ask 40.28 x 1100
  • Day's Range 35.39 - 36.17
  • 52 Week Range 29.32 - 52.76
  • Volume 539,929
  • Avg. Volume 1,043,877
  • Market Cap (intraday) 2.06B
  • Beta (5Y Monthly) 1.90
  • PE Ratio (TTM) --
  • EPS (TTM) -14.64
  • Earnings Date Aug 5, 2025 - Aug 11, 2025
  • Forward Dividend & Yield --
  • Ex-Dividend Date --
  • 1y Target Est 56.50

Enovis Corporation operates as a medical technology company focus on developing clinically differentiated solutions in the United States and internationally. It operates through two segments: Prevention and Recovery, and Reconstructive segments. The company's Prevention and Recovery segment offers orthopedic solutions and recovery sciences including rigid and soft orthopedic bracing, hot and cold therapy, bone growth stimulators, vascular therapy systems and compression garments, therapeutic shoes and inserts, electrical stimulators management, and physical therapy products which are used by orthopedic specialists, surgeons, primary care physicians, pain management specialists, physical therapists, podiatrists, chiropractors, athletic trainers, and other healthcare professionals. Its Reconstructive segment operates surgical implant business, which includes a suite of reconstructive joint products for the hip, knee, shoulder, elbow, foot, ankle, and finger, as well as surgical productivity tools. It also manufactures and distributes medical devices which are used for reconstructive surgery, rehabilitation, pain management, and physical therapy. It distributes its products through independent distributors and directly under the ESAB and DJO brands. The company was formerly known as Colfax Corporation. Enovis Corporation was founded in 1995 and is headquartered in Wilmington, Delaware.

www.enovis.com

7,367

Full Time Employees

December 31

Fiscal Year Ends

Recent News: ENOV

View More

Performance Overview: ENOV

Trailing total returns as of 5/16/2025, which may include dividends or other distributions. Benchmark is S&P 500 (^GSPC) .

YTD Return

ENOV
17.82%
S&P 500 (^GSPC)
1.30%

1-Year Return

ENOV
30.92%
S&P 500 (^GSPC)
12.48%

3-Year Return

ENOV
43.16%
S&P 500 (^GSPC)
48.66%

5-Year Return

ENOV
17.09%
S&P 500 (^GSPC)
108.07%

Compare To: ENOV

Select to analyze similar companies using key performance metrics; select up to 4 stocks.

Statistics: ENOV

View More

Valuation Measures

Annual
As of 5/16/2025
  • Market Cap

    2.06B

  • Enterprise Value

    3.48B

  • Trailing P/E

    --

  • Forward P/E

    11.75

  • PEG Ratio (5yr expected)

    --

  • Price/Sales (ttm)

    0.94

  • Price/Book (mrq)

    0.79

  • Enterprise Value/Revenue

    1.62

  • Enterprise Value/EBITDA

    --

Financial Highlights

Profitability and Income Statement

  • Profit Margin

    -37.65%

  • Return on Assets (ttm)

    0.92%

  • Return on Equity (ttm)

    -27.35%

  • Revenue (ttm)

    2.15B

  • Net Income Avi to Common (ttm)

    -811.94M

  • Diluted EPS (ttm)

    -14.64

Balance Sheet and Cash Flow

  • Total Cash (mrq)

    38.46M

  • Total Debt/Equity (mrq)

    55.68%

  • Levered Free Cash Flow (ttm)

    -41.37M

Research Analysis: ENOV

View More

Company Insights: ENOV

Research Reports: ENOV

View More

People Also Watch